Literature DB >> 12594698

Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.

Fernando Boccalandro1, Muhammad Amhad, Richard W Smalling, Stefano Sdringola.   

Abstract

The use of radiographic contrast during cardiac catheterization can cause acute renal failure with an increase in morbidity and mortality. Prophylactic acetylcysteine plus intravenous hydration have been shown to prevent contrast-induced nephropathy (CIN) in patients with chronic renal failure undergoing computed tomography scan, who receive low doses of intravenous contrast. Whether the use of prophylactic acetylcysteine can decrease the incidence of CIN when larger doses of contrast are used remains to be determined. We sought to evaluate whether the prophylactic administration of acetylcysteine plus intravenous hydration is superior to intravenous hydration alone in prevention of CIN in patients with chronic renal failure undergoing cardiac catheterization and receiving moderate to high doses of intravenous contrast (> 1 cc/kg). Seventy-three consecutive patients with renal insufficiency who received intravenous hydration and 600 mg of acetylcysteine twice a day 24 hr before and the day of the cardiac catheterization were compared with 106 consecutive patients who received hydration alone. Baseline and 48-hr serum creatinine concentrations were compared between the two groups before and after cardiac catheterization. Multivariate and univariate analysis were performed to assess the effects of acetylcysteine and other clinical variables in the change of serum creatinine after the procedure. Both groups had comparable clinical characteristics and received similar volumes of intravenous hydration. The volume of contrast used was similar for the two groups (2.2 +/- 1.7 vs. 2.3 +/- 1.5 cc/kg; P = 0.67). A mean change in serum creatinine of 0.17 +/- 0.54 mg/dl for the acetylcysteine group vs. 0.19 +/- 0.40 mg/dl for the control group (P = 0.77) was observed at 48 hr. The incidence CIN was 13% in the acetylcysteine vs. 12% in the control group (P = 0.84). Acetylcysteine, whether analyzed with multivariate or univariate analysis, failed to demonstrate a significant effect in the change of serum creatinine after cardiac catheterization. In patients with chronic renal insufficiency, acetylcysteine in a dose of 600 mg twice a day before and after cardiac catheterization, along with intravenous fluids, is as effective as fluids alone in the prevention of CIN when moderate to high doses of contrast are used. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594698     DOI: 10.1002/ccd.10389

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  20 in total

1.  Does the prophylactic use of N-acetylcysteine prevent contrast nephropathy in patients with renal insufficiency?

Authors:  Irene Wai Yan Ma; Michelle Hladunewich
Journal:  CMAJ       Date:  2004-04-13       Impact factor: 8.262

Review 2.  How to protect from contrast media-induced nephropathy?

Authors:  B Scheller
Journal:  Clin Res Cardiol       Date:  2007-03       Impact factor: 5.460

3.  Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.

Authors:  Alper O Onbasili; Yavuz Yeniceriglu; Pinar Agaoglu; Aslihan Karul; Tarkan Tekten; Harun Akar; Guzel Discigil
Journal:  Heart       Date:  2006-10-25       Impact factor: 5.994

4.  Safety of gadodiamide mixed with a small quantity of iohexol in patients with impaired renal function undergoing coronary angiography.

Authors:  Cem Barcin; Hurkan Kursaklioglu; Atilla Iyisoy; Sedat Kose; Hasan Fehmi Tore; Ersoy Isik
Journal:  Heart Vessels       Date:  2006-05       Impact factor: 2.037

Review 5.  Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2006-05-04       Impact factor: 5.315

6.  N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial.

Authors:  V O Gomes; C E Poli de Figueredo; P Caramori; R Lasevitch; L C Bodanese; A Araújo; A P Röedel; A P Caramori; F S Brito; H G Bezerra; P Nery; A Brizolara
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

7.  Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography.

Authors:  Yao-Min Hung; Shoa-Lin Lin; Shih-Yuan Hung; Wei-Chun Huang; Paul Yung-Pou Wang
Journal:  World J Cardiol       Date:  2012-05-26

8.  No increased risk for contrast-induced nephropathy after multiple CT perfusion studies of the brain with a nonionic, dimeric, iso-osmolal contrast medium.

Authors:  S Langner; S Stumpe; M Kirsch; M Petrik; N Hosten
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-04       Impact factor: 3.825

9.  Contrast media-induced nephropathy: case report and review of the literature focusing on pathogenesis.

Authors:  G Efstratiadis; P Pateinakis; G Tambakoudis; A Pantzaki; D Economidou; D Memmos
Journal:  Hippokratia       Date:  2008-04       Impact factor: 0.471

Review 10.  Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.

Authors:  Steven D Weisbord; Martin Gallagher; James Kaufman; Alan Cass; Chirag R Parikh; Glenn M Chertow; Kendrick A Shunk; Peter A McCullough; Michael J Fine; Maria K Mor; Robert A Lew; Grant D Huang; Todd A Conner; Mary T Brophy; Joanne Lee; Susan Soliva; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-09       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.